Toll-like receptor activation by helminths or helminth products to alleviate inflammatory bowel disease

Parasites and Vectors

Volumn 4, Issue 1, 2011, Pages

  Sun, Shumin ^a,b   Wang, Xuelin ^a   Wu, Xiuping ^a   Zhao, Ying ^a   Wang, Feng ^a   Liu, Xiaolei ^a   Song, Yanxia ^a   Wu, Zhiliang ^c   Liu, Mingyuan ^a  

^a JILIN UNIVERSITY   (China)

^b INNER MONGOLIA UNIVERSITY FOR NATIONALITIES   (China)

^c GIFU UNIVERSITY   (Japan)

Author keywords

Helminth; Inflammatory Bowel Disease; Toll Like Receptors

Indexed keywords

TOLL LIKE RECEPTOR; HELMINTH PROTEIN;

AUTOIMMUNE DISEASE; ENTERITIS; HELMINTHIASIS; HOST RESISTANCE; HUMAN; IMMUNOPATHOLOGY; NONHUMAN; REVIEW; ANIMAL; HELMINTH; IMMUNOLOGY; PARASITOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

VERMES;

ANIMALS; HELMINTH PROTEINS; HELMINTHIASIS; HELMINTHS; HUMANS; INFLAMMATORY BOWEL DISEASES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 80053357016     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/1756-3305-4-186     Document Type: Review

References (82)

1. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK, Immunology 2008 125 145 153 18798918
2. Innate and adaptive immune connections in inflammatory bowel diseases. Rakoff-Nahoum S, Bousvaros A, Curr Opin Gastroenterol 2010 26 572 577 10.1097/MOG.0b013e32833f126d 20871398
3. Intestinal inflammation and cancer. Ullman TA, Itzkowitz SH, Gastroenterology 2011 140 1807 1816 10.1053/j.gastro.2011.01.057 21530747
4. The genetics and immunopathogenesis of inflammatory bowel disease. Cho JH, Nat Rev Immunol 2008 8 458 466 10.1038/nri2340 18500230 (Pubitemid 351733422)
5. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Loftus EV Jr, Gastroenterology 2004 126 1504 1517 10.1053/j.gastro.2004.01.063 15168363 (Pubitemid 38649869)
6. Hay fever, hygiene, and household size. Strachan DP, BMJ 1989 299 1259 1260 10.1136/bmj.299.6710.1259 2513902 (Pubitemid 19280051)
7. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Okada H, Kuhn C, Feillet H, Bach JF, Clin Exp Immunol 2010 160 1 9 20415844
8. The fundamental basis of inflammatory bowel disease. Strober W, Fuss I, Mannon P, J Clin Invest 2007 117 514 521 10.1172/JCI30587 17332878 (Pubitemid 46348505)
9. Helminths and the IBD hygiene hypothesis. Weinstock JV, Elliott DE, Inflamm Bowel Dis 2009 15 128 133 10.1002/ibd.20633 18680198
10. Do helminth parasites protect against atopy and allergic disease? Flohr C, Quinnell RJ, Britton J, Clin Exp Allergy 2009 39 20 32 10.1111/j.1365-2222. 2008.03134.x 19128351
11. An inverse relationship between autoimmune liver diseases and Strongyloides stercoralis infection. Aoyama H, Hirata T, Sakugawa H, Watanabe T, Miyagi S, Maeshiro T, Chinen T, Kawane M, Zaha O, Nakayoshi T, Kinjo F, Fujita J, Am J Trop Med Hyg 2007 76 972 976 17488925 (Pubitemid 351627689)
12. Parasitic helminths: new weapons against immunological disorders. Osada Y, Kanazawa T, J Biomed Biotechnol 2010 2010 743 758
13. Trichinella inflammatory myopathy: host or parasite strategy? Bruschi F, Chiumiento L, Parasit Vectors 2011 4 42 10.1186/1756-3305-4-42 21429196
14. Therapeutic immunomodulators from nematode parasites. Harnett W, Harnett MM, Expert Rev Mol Med 2008 19 10 23
15. Intestinal nematode infection ameliorates experimental colitis in mice. Khan WI, Blennerhasset PA, Varghese AK, Chowdhury SK, Infect Immun 2002 70 5931 5937 10.1128/IAI.70.11.5931-5937.2002 12379667 (Pubitemid 35192680)
16. Tapeworm infection reduces epithelial ion transport abnormalities in murine dextran sulfate sodium-induced colitis. Reardon C, Sanchez A, Hogaboam CM, McKay DM, Infect Immun 2001 69 4417 4423 10.1128/IAI.69.7.4417-4423.2001 11401981 (Pubitemid 32574440)
17. Therapeutic potential of helminthes soluble proteins in TNBS-induced colitis in mice. Ruyssers NE, De Winter BY, De Man JG, Loukas A, Pearson MS, Weinstock JV, Inflamm Bowel Dis 2009 15 491 500 10.1002/ibd.20787 19023900
18. Helminths as governors of immune-mediated inflammation. Elliott DE, Summers RW, Weinstock JV, Int J Parasitol 2007 37 457 464 10.1016/j.ijpara.2006. 12.009 17313951 (Pubitemid 46399709)
19. Trichuris suis therapy in Crohn's disease. Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV, Gut 2005 54 87 90 10.1136/gut.2004.041749 15591509 (Pubitemid 40007223)
20. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Summers RW, Elliott DE, Qadir K, Urban JF Jr, Thompson R, Weinstock JV, Am J Gastroenterol 2003 98 2034 2041 10.1111/j.1572-0241.2003.07660.x 14499784 (Pubitemid 37185802)
21. Review series on helminths, immune modulation and the hygiene hypothesis: the broader implications of the hygiene hypothesis. Rook GA, Immunology 2009 126 3 11 10.1111/j.1365-2567.2008.03007.x 19120493
22. Signaling pathways associated with inflammatory bowel disease. Wei J, Feng J, Recent Pat Inflamm Allergy Drug Discov 2010 4 105 17 10.2174/187221310791163071 20001899
23. New insights into the pathogenesis of Crohn's disease: are they relevant for therapeutic options? Vavricka SR, Rogler G, Swiss Med Wkly 2009 139 527 534 19838869
24. Inflammatory bowel diseases: an immunological approach. Sepúlveda SE, Beltrán CJ, Peralta A, Rivas P, Rojas N, Figueroa C, Quera R, Hermoso MA, Rev Med Chil 2008 136 367 75 18575665
25. Toll-like receptors in inflammatory bowel diseases: a decade later. Cario E, Inflamm Bowel Dis 2010 16 1583 1597 10.1002/ibd.21282 20803699
26. Therapeutic benefits of regulating inflammation in autoimmunity. Nikoopour E, Schwartz JA, Singh B, Inflamm Allergy Drug Targets 2008 7 203 210 10.2174/187152808785748155 18782028
27. Microbial host interactions in IBD: implications for pathogenesis and therapy. Sartor RB, Muehlbauer M, Curr Gastroenterol Rep 2007 9 497 507 10.1007/s11894-007-0066-4 18377803 (Pubitemid 351795708)
28. Therapeutic impact of toll-like receptors on inflammatory bowel diseases: a multiple-edged sword. Cario E, Inflamm Bowel Dis 2008 14 411 421 10.1002/ibd.20294 17941072 (Pubitemid 351441332)
29. Therapeutic targeting of toll-like receptors in gastrointestinal inflammation. Ishihara S, Rumi MA, Ortega-Cava CF, Kazumori H, Kadowaki Y, Ishimura N, Kinoshita Y, Curr Pharm Des 2006 12 4215 4228 10.2174/ 138161206778743448 17100624 (Pubitemid 44669750)
30. Toll-like receptors in innate immunity. Takeda K, Akira S, Int Immunol 2005 17 1 14 15585605
31. Does TLR2 regulate intestinal inflammation? Mowat AM, Eur J Immunol 2010 40 318 320 10.1002/eji.200940232 20039306
32. Induction of cytokines and chemokines by Toll-like receptor signaling: strategies for control of inflammation. Zeytun A, Chaudhary A, Pardington P, Cary R, Gupta G, Crit Rev Immunol 2010 30 53 67 20370620
33. A toll-like receptor that prevents infection by uropathogenic bacteria. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, Ghosh S, Science 2004 303 1522 1526 10.1126/science.1094351 15001781 (Pubitemid 38314423)
34. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC, Podolsky DK, J Immunol 2000 164 966 972 10623846 (Pubitemid 30043724)
35. Intestinal myofibroblasts in innate immune responses of the intestine. Otte JM, Rosenberg IM, Podolsky DK, Gastroenterology 2003 124 1866 1878 10.1016/S0016-5085(03)00403-7 12806620 (Pubitemid 36666782)
36. The c.1-260C > T promoter variant of CD14 but not the c.896A > G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Baumgart DC, Buning C, Geerdts L, Schmidt HH, Genschel J, Fiedler T, Gentz E, Molnar T, Nagy F, Lonovics J, Lochs H, Wiedenmann B, Nickel R, Witt H, Dignass A, Digestio 2007 76 196 202 10.1159/000112646 (Pubitemid 351351673)
37. Heligmosomoides polygyrus induces TLR4 on murine mucosal T cells that produce TGFbeta after lipopolysaccharide stimulation. Ince MN, Elliott DE, Setiawan T, Blum A, Metwali A, Wang Y, Urban JF Jr, Weinstock JV, J Immunol 2006 176 726 729 16393954 (Pubitemid 43099667)
38. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, Kamm MA, Stagg AJ, Gastroenterology 2005 129 50 65 10.1053/j.gastro.2005.05.013 16012934 (Pubitemid 41002042)
39. Toll-like receptors in inflammatory bowel disease- stepping into uncharted territory. Levin A, Shibolet O, World J Gastroenterol 2008 14 5149 153 10.3748/wjg.14.5149 18777591
40. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Kawai T, Akira S, Immunity 2011 34 637 650 10.1016/j.immuni.2011.05.006 21616434
41. Pathogen recognition through natural immunity. Takeda K, Nihon Jibiinkoka Gakkai Kaiho 2011 114 1 6 21500598
42. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Sadanaga A, Nakashima H, Akahoshi M, Masutani K, Miyake K, Igawa T, Sugiyama N, Niiro H, Harada M, Arthritis Rheum 2007 56 1618 1628 10.1002/art.22571 17469144 (Pubitemid 46764091)
43. Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. Su SB, Silver PB, Grajewski RS, Agarwal RK, Tang J, Chan CC, Caspi RR, J Immunol 2005 175 6303 6310 16272281 (Pubitemid 41598869)
44. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S, Immunity 1998 9 143 150 10.1016/S1074-7613(00) 80596-8 9697844 (Pubitemid 28361303)
45. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL, Eur J Immunol 2007 37 3582 3586 10.1002/eji.200737815 18034431
46. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ, J Am Soc Nephro 2007 18 1721 1731 10.1681/ASN.2006101162 (Pubitemid 46870309)
47. Toll-like receptor signaling pathways-therapeutic opportunities. Zhu J, Mohan C, Mediators Inflamm 2010 781235 1 7
48. TRIF mediates Toll-like receptor 5-induced signaling in intestinal epithelial cells. Choi YJ, Im E, Chung HK, Pothoulakis C, Rhee SH, J Biol Chem 2010 285 37570 37578 10.1074/jbc.M110.158394 20855887
49. Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9 -1237T/C polymorphism is associated with Helicobacter pylori-induced gastric disease. Ng MT, Van't Hof R, Crockett JC, Hope ME, Berry S, Thomson J, McLean MH, McColl KE, El-Omar EM, Hold GL, Infect Immun 2010 78 1345 1352 10.1128/IAI.01226-09 20038537
50. Lipoprotein biosynthesis as a target for anti-Wolbachia treatment of filarial nematodes. Johnston KL, Wu B, Guimarães A, Ford L, Slatko BE, Taylor MJ, Parasit Vectors 2010 3 99 10.1186/1756-3305-3-99 20946650
51. Activation and regulation of toll-like receptors (TLRs) by helminth parasites. Venugopal PG, Nutman TB, Semnani RT, Immunol Res 2009 43 252 263 10.1007/s12026-008-8079-0 18982454
52. Diminished expression and function of TLR in lymphatic filariasis: a novel mechanism of immune dysregulation. Babu S, Blauvelt CP, Kumaraswami V, Nutman TB, J Immunol 2005 175 1170 1176 16002719 (Pubitemid 41095004)
53. Preventive effects of Schistosoma japonicum ova on trinitrobenzenesulfonic acid-induced colitis and bacterial translocation in mice. Zhao Y, Zhang S, Jiang L, Jiang J, Liu H, J Gastroenterol Hepatol 2009 24 1775 1780 10.1111/j.1440-1746.2009.05986.x 20136961
54. Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Iliev ID, Spadoni I, Mileti E, Matteoli G, Gut 2009 58 1481 -1489 10.1136/gut.2008.175166 19570762
55. Autophagy is required for toll-like receptor-mediated interleukin-8 production in intestinal epithelial cells. Li YY, Ishihara S, Aziz MM, Oka A, Int J Mol Med 2011 27 337 344 21225224
56. Toll-like receptor 4-mediated signaling by epithelial surfaces: necessity or threat? Bäckhed F, Hornef M, Microbes Infect 2003 5 951 959 10.1016/S1286-4579(03)00189-8 12941387 (Pubitemid 36986570)
57. Pathogen recognition receptors, cancer and inflammation in the gut. Fukata M, Abreu MT, Curr Opin Pharmacol 2009 9 680 687 10.1016/j.coph.2009.09. 006 19828376
58. Regulation of toll-like receptors in intestinal epithelial cells by stress and Toxoplasma gondii infection. Gopal R, Birdsell D, Monroy FP, Parasite Immunol 2008 30 563 576 10.1111/j.1365-3024.2008.01055.x 19067837
59. Molecular analysis of commensal host-microbial relationships in the intestine. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI, Science 2001 291 881 884 10.1126/science.291.5505.881 11157169 (Pubitemid 32120760)
60. Current views of toll-like receptor signaling pathways. Yamamoto M, Takeda K, Gastroenterol Res Pract 2010 240365 1 8
61. Mucin and Toll-like receptors in host defense against intestinal parasites. Moncada DM, Kammanadiminti SJ, Chadee K, Trends Parasitol 2003 19 305 311 10.1016/S1471-4922(03)00122-3 12855381 (Pubitemid 36833218)
62. Adenocarcinomas associated with perianal fistulae in Crohn's disease have a rectal, not an anal, immunophenotype. Nishigami T, Kataoka TR, Ikeuchi H, Torii I, Sato A, Tomita N, Tsujimura T, Pathology 2011 43 36 39 10.1097/PAT.0b013e328340e4d6 21240063
63. Altered expression of goblet cell- and mucin glycosylation-related genes in the intestinal epithelium during infection with the nematode Nippostrongylus brasiliensis in rat. Yamauchi J, Kawai Y, Yamada M, Uchikawa R, Tegoshi T, Arizono N, APMIS 2006 114 270 278 10.1111/j.1600-0463.2006.apm-353.x 16689826
64. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Cario E, Gerken G, Podolsky DK, Gastroenterology 2004 127 224 238 10.1053/j.gastro.2004.04.015 15236188 (Pubitemid 38962290)
65. Toll-like receptor 2 and Muc2 expression on human intestinal epithelial cells by Gymnophalloides seoi adult antigen. Lee KD, Guk SM, Chai JY, J Parasitol 2010 96 58 66 10.1645/GE-2195.1 19737027
66. Restless T cells sniff and go. Mustelin T, Science 2006 313 1902 1903 10.1126/science.1133578 17008518 (Pubitemid 44497989)
67. Natural loss-of-function mutation of myeloid differentiation protein 88 disrupts its ability to form Myddosomes. Nagpal K, Plantinga TS, Sirois CM, Monks BG, Latz E, Netea MG, Golenbock DT, J Biol Chem 2011 286 11875 11882 10.1074/jbc.M110.199653 21325272
68. Signalling adaptors used by Toll-like receptors: an update. Kenny EF, O'Neill LA, Cytokine 2008 43 342 349 10.1016/j.cyto.2008.07.010 18706831
69. Contribution of nano-copper particles to in vivo liver dysfunction and cellular damage: Role of IB/NF-B, MAPKs and mitochondrial signal. Manna P, Ghosh M, Ghosh J, Das J, Sil PC, Nanotoxicology 2011 552124 1 21
70. The Toll-IL-1 receptor adaptor family grows to five members. O'Neill LA, Fitzgerald KA, Bowie AG, Trends Immunol 2003 24 286 290 10.1016/S1471-4906(03) 00115-7 12810098 (Pubitemid 36694875)
71. Concurrent infection with Schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats. Moreels TG, Nieuwendijk RJ, De Man JG, De Winter BY, Herman AG, Van Marck EA, Gut 2004 53 99 107 10.1136/gut.53.1.99 14684583 (Pubitemid 38083017)
72. DC-SIGN mediates binding of dendritic cells to authentic pseudo-LewisY glycolipids of Schistosoma mansoni cercariae, the first parasite-specific ligand of DC-SIGN. Meyer S, van Liempt E, Imberty A, van Kooyk Y, Geyer H, Geyer R, van Die I, J Biol Chem 2005 280 37349 37359 10.1074/jbc.M507100200 16155001 (Pubitemid 41642340)
73. Excretory-secretory products (ESP) from Fasciola hepatica induce tolerogenic properties in myeloid dendritic cells. Falcán C, Carranza F, Martínez FF, Vet Immunol Immunopathol 2010 137 36 46 10.1016/j.vetimm. 2010.04.007 20447697
74. Cystatin cures visceral leishmaniasis by NF-B-mediated proinflammatory response through co-ordination of TLR/MyD88 signaling with p105-Tpl2-ERK pathway. Kar S, Ukil A, Das PK, Eur J Immunol 2011 41 116 127 10.1002/eji.201040533 21182083
75. Helminth-derived immunomodulators: can understanding the worm produce the pill? Harnett W, Harnett MM, Nat Rev Immunol 2010 10 278 284 10.1038/nri2730 20224568
76. Future therapeutic approaches for inflammatory bowel diseases. Plevy SE, Targan SR, Gastroenterology 2011 140 1838 1846 10.1053/j.gastro.2011.02.014 21530750
77. Commensal-associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal epithelium. Cario E, Brown D, McKee M, Lynch-Devaney K, Gerken G, Podolsky DK, Am J Patho 2002 160 165 173 10.1016/S0002-9440(10)64360-X (Pubitemid 34052277)
78. Schistosoma mansoni worm glycolipids induce an inflammatory phenotype in human dendritic cells by cooperation of TLR4 and DC-SIGN. van Stijn CM, Meyer S, van den Broek M, Bruijns SC, van Kooyk Y, Geyer R, van Die I, Mol Immunol 2010 7-8 1544 1552
79. Helminth cysteine proteases inhibit TRIF-dependent activation of macrophages via degradation of TLR3. Donnelly S, O'Neill SM, Stack CM, Robinson MW, Turnbull L, Whitchurch C, Dalton JP, J Biol Chem 2010 285 3383 3392 10.1074/jbc.M109.060368 19923225
80. The "polarizing-tolerizing" mechanism of intestinal epithelium: its relevance to colonic homeostasis. Lee J, Gonzales-Navajas JM, Raz E, Semin Immunopathol 2008 30 3 9 10.1007/s00281-007-0099-7 18026955 (Pubitemid 351178626)
81. TNF-alpha activates MUC2 transcription via NF-kappa B but inhibits via JNK activation. Ahn DH, Crawley SC, Hokari R, Kato S, Yang SC, Li JD, Kim YS, Cell Physiol Biochem 2005 15 29 40 10.1159/000083636 15665513
82. Helminth antigens modulate immune responses in cells from multiple sclerosis patients through TLR2-dependent mechanisms. Correale J, Farez M, J Immunol 2009 183 5999 6012 10.4049/jimmunol.0900897 19812189